The Gene Editor That Rewrites Your DNA Like a Word Processor

Base editing, CRISPR's younger sibling, improved things. It can chemically convert one DNA letter to another without making a full cut. But it has limitations: it can only make certain types of letter swaps, and it sometimes edits neighboring letters it wasn't supposed to touch (called bystander edits).

Prime editing is the next evolution. Developed at the Broad Institute, it uses a modified Cas9 protein that only nicks one strand of DNA (not both) plus a special guide RNA that carries a built-in template of the correct sequence. Think of it like a biological find-and-replace function. The editor locates the typo, makes a tiny nick, and uses the template to write in the correct letters. No double-strand break. No bystander edits. All 12 possible single-letter DNA swaps are on the table, plus small insertions and deletions.

In theory, it's the most precise gene editor humans have ever built. The question has always been whether it could work inside a living person.

What the Trial Actually Looks Like

PM-647 is designed as a one-time intravenous infusion. One shot, delivered into a vein, targeted at the liver. The Phase 1/2 trial will be a global, single-arm, open-label study with ascending doses, meaning researchers will start low and carefully increase the dose as they confirm safety.

The first patients enrolled will be adults with lung-only AATD: people whose lungs are affected but whose livers are still in relatively good shape. Once the therapy shows acceptable tolerability in that group, the trial will expand to include adults with significant liver disease, with or without lung problems. Initial clinical data are expected in 2027.

It's a smart, cautious design. Start with the patients who have less organ damage at risk, prove the therapy is safe, then move to the sicker population where the unmet need is arguably greatest.

A Crowded (and Exciting) Neighborhood

Prime Medicine isn't the only company trying to edit genes inside the liver. The in vivo liver editing space has gotten surprisingly competitive over the past two years.

Intellia Therapeutics is the current leader, with its CRISPR-based therapy NTLA-2001 already in Phase III for hereditary transthyretin amyloidosis (hATTR) and NTLA-2002 for hereditary angioedema, which has a BLA accepted by the FDA with a PDUFA date of March 10, 2027. CRISPR Therapeutics has shown promising Phase 1a data for CTX310, which targets ANGPTL3 for cardiovascular disease. Verve Therapeutics pioneered in vivo base editing for PCSK9, though its lead program hit some clinical speed bumps. And newer entrants like YolTech are nipping at Verve's heels with their own PCSK9 editing approaches.

But most of these competitors are focused on cardiometabolic targets: cholesterol genes, triglyceride pathways, cardiovascular risk factors. Prime Medicine is carving out a different lane entirely, going after a rare genetic liver disease where the goal isn't to knock out a gene but to fix it. That distinction matters. Correcting a mutation is harder than disabling one, and prime editing is uniquely suited for the job.

The Money Behind the Mission

Prime Medicine has been busy building a financial runway to match its scientific ambitions. A September 2024 deal with Bristol Myers Squibb brought in $55 million in cash upfront, a $55 million equity investment, and potential milestone payments exceeding $3.5 billion for a collaboration on T-cell therapies. The Cystic Fibrosis Foundation has also backed Prime's cystic fibrosis work with agreements totaling up to $39 million across two deals.

The company reported roughly $191.4 million in cash and investments at the end of 2025, with runway extending into 2027. A $140 million follow-on offering in 2026 added further cushion. Analysts from Citizens, TD Cowen, H.C. Wainwright, and BMO Capital all reiterated favorable ratings after the IND clearance, and the stock reportedly jumped on the news.

Why This Matters Beyond One Disease

PM-647 isn't just a clinical candidate. It's a proof of concept for an entire technology. If prime editing can safely and effectively correct a single-letter mutation in a living human's liver, the implications ripple outward to thousands of other genetic diseases caused by similar point mutations. Wilson's disease (Prime's other lead program, also targeting an IND in 2026) could be next. And the platform's versatility means the company isn't limited to one type of edit or one organ forever.

The gene editing field has been building toward this moment for years: a tool precise enough to fix a typo without rewriting the whole page, delivered directly into the body without removing cells first. Prime Medicine is now one clinical trial away from proving whether that vision can survive contact with human biology.

The data readout in 2027 won't just tell us about PM-647. It will tell us whether prime editing is ready for prime time.

The Cancer Therapy That's Curing Lupus

Adicet Bio's off-the-shelf CAR-T therapy, originally built for cancer, just produced durable lupus remissions in a Phase 1 trial. The results could validate the "immune reset" approach and upend decades of chronic immunosuppression.